Apyx Medical Corporation, a leader in surgical aesthetics marketed as Renuvion and AYON, reported strong Q1 2026 results driven by international demand, particularly in South Korea following regulatory approval in December 2025. The company raised its full-year 2026 revenue guidance to $60 million, up 32.4% year-over-year.
Surgical Aesthetics revenue increased 36.1% to $10.7 million, driven by U.S. adoption of the AYON Body Contouring System, increased international generator sales, and higher single-use handpiece volumes in both domestic and international markets. These gains were partially offset by declines in domestic generator sales, including upgrades to the Apyx One Console where AYON was not part of the sale, and similar upgrades in international markets.
OEM segment revenue also increased for the quarter due to higher sales volume to existing customers. However, the company expects OEM revenue to decline over the year and continue this trend over time as it focuses more on Surgical Aesthetics.
International sales exceeded expectations, driven partly by sales of the Apyx One Console and single-use handpieces in South Korea. The cosmetic surgery market in South Korea is estimated to be an attractive growth market.
“Our first quarter results reflect continued execution against our commercial strategy, with strong revenue growth driven by adoption of AYON in the U.S., increasing demand for Renuvion internationally and an increase in handpieces worldwide,” said Charlie Goodwin, President and Chief Executive Officer. “During the quarter, our team delivered on several fronts, including growing Surgical Aesthetic sales including expansion of AYON and exceeding expectations in key international markets such as South Korea. Taken together, this performance reinforces our confidence in the business and supports our decision to raise our revenue outlook for the full year 2026.”
Gross margin improved for the quarter due to a favorable mix shift toward Surgical Aesthetics and product mix within the OEM segment, partially offset by geographic mix with higher international sales and tariffs that began affecting the company in the second half of 2025.
Surgical Aesthetics revenue is expected to be in a range, while OEM revenue is expected to be approximately a certain amount for the full year. The company has shown a pattern of favorable market reactions to earnings reports highlighting Surgical Aesthetics growth and improved profitability metrics.
Source: Read the original report | Published: May 07, 2026